\n
\n
London, Oct 11 (PTI) An antibody combination treatment delivered through an injection has shown statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19, AstraZeneca reported on Monday.<\/p>\n
The British-Swedish biopharmaceutical major said its TACKLE Phase III COVID-19 treatment trial for AZD7442 had shown that the treatment met the primary endpoint .<\/p>\n
A dose of 600mg of AZD7442 given by intramuscular (IM) injection reduced the risk of developing severe COVID-19 or death (from any cause) by 50 per cent, compared to placebo in outpatients who had been symptomatic for seven days or less.<\/p>\n
With continued cases of serious COVID-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations from getting COVID-19 and can also help prevent progression to severe disease, said Hugh Montgomery, Professor of Intensive Care Medicine at University College London, and TACKLE principal investigator.<\/p>\n
These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic, he said.<\/p>\n
AZD7442 is dubbed as the first long acting antibody (LAAB) with Phase III data to demonstrate benefit in both prophylaxis (prevention) and treatment of COVID-19 and is easily administered by IM injection.<\/p>\n
A total of 90 per cent of participants enrolled were from populations at high risk of progression to severe COVID-19, including those with comorbidities.<\/p>\n
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: These important results for AZD7442, our long-acting antibody combination, add to the growing body of evidence for use of this therapy in both prevention and treatment of COVID-19.<\/p>\n
An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months.<\/p>\n
The LAAB was generally well tolerated in the trial, AstraZeneca said.<\/p>\n
In a prespecified analysis of participants who received treatment within five days of symptom onset, AZD7442 reduced the risk of developing severe COVID-19 or death (from any cause) by 67 per cent compared to placebo.<\/p>\n
TACKLE included 903 participants in a 1:1 randomisation AZD7442 to placebo and the primary analysis was based on 822 participants.<\/p>\n
AstraZeneca said it will be discussing the data with health authorities and its full findings to be published in a medical journal in due course.<\/p>\n
Last week, the company had announced that it submitted a request to the US Food and Drug Administration (USFDA) for Emergency Use Authorisation for AZD7442 for prophylaxis or treatment of COVID-19.<\/p>\n","protected":false},"excerpt":{"rendered":"
London, Oct 11 (PTI) An antibody combination treatment delivered through an injection has shown statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19, AstraZeneca reported on Monday. The British-Swedish biopharmaceutical major said its TACKLE Phase III COVID-19 treatment trial for AZD7442 had shown that the treatment […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":{"0":"post-173990","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-world"},"_links":{"self":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/posts\/173990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/comments?post=173990"}],"version-history":[{"count":0,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/posts\/173990\/revisions"}],"wp:attachment":[{"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/media?parent=173990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/categories?post=173990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arunachaltimes.in\/index.php\/wp-json\/wp\/v2\/tags?post=173990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}